Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IRMD?
Source: Fool
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRMD
Wall Street analysts forecast IRMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 83.440
Low
98.00
Averages
99.00
High
100.00
Current: 83.440
Low
98.00
Averages
99.00
High
100.00
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IRadimed Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: IRadimed reported Q1 2026 revenue of $22 million, reflecting a 13% increase over Q1 2025, demonstrating solid execution across product lines, particularly from the 3860 pump system and the growing Ferro-magnetic Detection System.
- Product Transition Trends: CEO Susi highlighted that the average selling price (ASP) for the 3870 pump is showing an initial lift closer to 20%, exceeding the anticipated 10% to 14%, with over half of new business coming from Quad four-pump systems, indicating strong market demand for the new product.
- Robust Profitability: The company achieved a gross profit of $16.8 million with a gross margin of 77% in Q1, and net income was $5.8 million, or $0.45 per diluted share, showcasing effective cost control and profitability.
- Optimistic Outlook: For Q2 2026, the company expects revenue between $20 million and $21 million, with a full-year revenue target of $91 million to $96 million; despite short-term production constraints, management remains optimistic about long-term growth prospects.
See More
IRADIMED Reports Q1 Adjusted EPS of $0.49
- Market Adjustment: The market has seen a recent adjustment with a decrease in the adjusted EPS to $0.49.
- Investor Sentiment: This adjustment may impact investor sentiment and future market strategies.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
Iradimed Reports First Quarter Earnings Growth
- Significant Earnings Growth: Iradimed Corporation reported a net income of $5.82 million for the first quarter, translating to an earnings per share (EPS) of $0.45, which marks a substantial increase from last year's $4.69 million and $0.37 per share, reflecting enhanced competitiveness in the market.
- Adjusted Earnings Performance: Excluding special items, the company reported adjusted earnings of $6.36 million, or $0.49 per share, indicating strengthened core business resilience and improved profitability.
- Strong Revenue Growth: The company's revenue rose 12.7% year-over-year to $21.98 million, up from $19.51 million last year, demonstrating sustained market demand that has driven sales growth.
- Optimistic Future Outlook: Iradimed provided guidance for next quarter's EPS in the range of $0.44 to $0.48, and full-year EPS guidance of $2.06 to $2.21, showcasing the company's confidence in future performance and ongoing growth potential.
See More
Iradimed Announces Quarterly Cash Dividend and Q1 Performance
- Quarterly Revenue Growth: Iradimed reported revenue of $22.0 million for Q1 2026, an increase of $2.5 million or 13% compared to the same period in 2025, indicating strong demand and growth potential in the MRI-compatible medical device market.
- Improved Profitability: The company reported a GAAP diluted EPS of $0.45 for Q1, a 22% increase year-over-year, while non-GAAP diluted EPS reached $0.49, up 17%, reflecting effective cost management and revenue growth enhancing profitability.
- Dividend Declaration: Iradimed's board declared a quarterly cash dividend of $0.20 per share for Q2 2026, payable on May 29, 2026, aimed at rewarding shareholders and boosting investor confidence.
- Future Guidance: The company reaffirmed its full-year 2026 revenue guidance of $91.0 million to $96.0 million, with GAAP diluted EPS expected between $1.90 and $2.05, and non-GAAP diluted EPS between $2.06 and $2.21, demonstrating confidence in future growth and positive market demand.
See More
iRadimed to Announce Q1 Earnings on May 1st
- Earnings Announcement: iRadimed (IRMD) is set to announce its Q1 2023 earnings on May 1st before market open, with a consensus EPS estimate of $0.45, reflecting a 7.1% year-over-year growth, indicating stable profitability.
- Revenue Expectations: Analysts forecast Q1 revenue to reach $21.32 million, representing a 9.3% year-over-year increase, which underscores the company's ongoing expansion and demand growth in the medical device sector.
- Performance Beat Record: Over the past two years, iRadimed has surpassed EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing its strong market performance and management capabilities.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw two upward revisions, indicating fluctuating market confidence in the company's future performance.
See More
IRadimed Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: IRadimed reported Q1 2026 revenue of $22 million, reflecting a 13% increase over Q1 2025, demonstrating solid execution across product lines, particularly from the 3860 pump system and the growing Ferro-magnetic Detection System.
- Product Transition Trends: CEO Susi highlighted that the average selling price (ASP) for the 3870 pump is showing an initial lift closer to 20%, exceeding the anticipated 10% to 14%, with over half of new business coming from Quad four-pump systems, indicating strong market demand for the new product.
- Robust Profitability: The company achieved a gross profit of $16.8 million with a gross margin of 77% in Q1, and net income was $5.8 million, or $0.45 per diluted share, showcasing effective cost control and profitability.
- Optimistic Outlook: For Q2 2026, the company expects revenue between $20 million and $21 million, with a full-year revenue target of $91 million to $96 million; despite short-term production constraints, management remains optimistic about long-term growth prospects.
See More
IRADIMED Reports Q1 Adjusted EPS of $0.49
- Market Adjustment: The market has seen a recent adjustment with a decrease in the adjusted EPS to $0.49.
- Investor Sentiment: This adjustment may impact investor sentiment and future market strategies.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
Iradimed Reports First Quarter Earnings Growth
- Significant Earnings Growth: Iradimed Corporation reported a net income of $5.82 million for the first quarter, translating to an earnings per share (EPS) of $0.45, which marks a substantial increase from last year's $4.69 million and $0.37 per share, reflecting enhanced competitiveness in the market.
- Adjusted Earnings Performance: Excluding special items, the company reported adjusted earnings of $6.36 million, or $0.49 per share, indicating strengthened core business resilience and improved profitability.
- Strong Revenue Growth: The company's revenue rose 12.7% year-over-year to $21.98 million, up from $19.51 million last year, demonstrating sustained market demand that has driven sales growth.
- Optimistic Future Outlook: Iradimed provided guidance for next quarter's EPS in the range of $0.44 to $0.48, and full-year EPS guidance of $2.06 to $2.21, showcasing the company's confidence in future performance and ongoing growth potential.
See More
Iradimed Announces Quarterly Cash Dividend and Q1 Performance
- Quarterly Revenue Growth: Iradimed reported revenue of $22.0 million for Q1 2026, an increase of $2.5 million or 13% compared to the same period in 2025, indicating strong demand and growth potential in the MRI-compatible medical device market.
- Improved Profitability: The company reported a GAAP diluted EPS of $0.45 for Q1, a 22% increase year-over-year, while non-GAAP diluted EPS reached $0.49, up 17%, reflecting effective cost management and revenue growth enhancing profitability.
- Dividend Declaration: Iradimed's board declared a quarterly cash dividend of $0.20 per share for Q2 2026, payable on May 29, 2026, aimed at rewarding shareholders and boosting investor confidence.
- Future Guidance: The company reaffirmed its full-year 2026 revenue guidance of $91.0 million to $96.0 million, with GAAP diluted EPS expected between $1.90 and $2.05, and non-GAAP diluted EPS between $2.06 and $2.21, demonstrating confidence in future growth and positive market demand.
See More
iRadimed to Announce Q1 Earnings on May 1st
- Earnings Announcement: iRadimed (IRMD) is set to announce its Q1 2023 earnings on May 1st before market open, with a consensus EPS estimate of $0.45, reflecting a 7.1% year-over-year growth, indicating stable profitability.
- Revenue Expectations: Analysts forecast Q1 revenue to reach $21.32 million, representing a 9.3% year-over-year increase, which underscores the company's ongoing expansion and demand growth in the medical device sector.
- Performance Beat Record: Over the past two years, iRadimed has surpassed EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing its strong market performance and management capabilities.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw two upward revisions, indicating fluctuating market confidence in the company's future performance.
See More
